The European Medicines Agency had already restricted
the use of Protelos — also known as Osseor or strontium ranelate —
last April but its pharmacovigilance committee said on Friday the
drug should no longer be used to treat osteoporosis at all.
The move follows an analysis which found that for every 1,000
patient-years there were four more cases of serious heart problems,
including heart attacks, and four more cases of blood clots among
patients taking the drug than those on placebo.
The recommendation will now be sent to the agency's Committee for
Medicinal Products for Human Use, which is expected to issue a final
opinion at its Jan. 20-23 meeting.
(Reporting by Ben Hirschler; editing by Pravin Char)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.